2 results
Approved WMOCompleted
To evaluate the safety, tolerability and pharmacokinetics of RO5428029 in healthy male subjects.
Approved WMOCompleted
The primary study objective is to determine whether Febuxostat daily 80-120 mg is better than Allopurinol daily 100-600 mg in inducing positive changes in Pulse Wave Velocity (PWV) after 36 weeks of treatment.